ArticleCancer discovery2018
Correction: Phase I Dose-Escalation Study of Taselisib, an Oral PI3KInhibitor, in Patients with Advanced Solid Tumors.
No numbers read from the abstract.
1 paper cites it
this papercites it
ArticleCancer discovery2018
No numbers read from the abstract.